Last updated: April 18, 2026

Application No. 18/408,956

GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF

Final Rejection

Filed

Jan 10, 2024

Examiner

MCDOWELL, BRIAN E

Art Unit

1624

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Deciphera Pharmaceuticals LLC

OA Round

2 (Final)

Interview Optional

— +30.3% interview lift. This examiner has a relatively high allow rate; a written response may suffice.

Based on 1102 resolved cases, 2023–2026

Examiner Intelligence

MCDOWELL, BRIAN E View full profile →

Grants 74% — above average

Career Allow Rate

818 granted / 1102 resolved

+14.2% vs TC avg

Strong +30% interview lift

Without

With

+30.3%

Interview Lift

resolved cases with interview

Typical timeline

2y 4m

Avg Prosecution

58 currently pending

Career history

1160

Total Applications

across all art units

Statute-Specific Performance

§101

1.0%

-39.0% vs TC avg

§103

15.0%

-25.0% vs TC avg

§102

19.5%

-20.5% vs TC avg

§112

47.6%

+7.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1102 resolved cases

Prosecution Timeline

Jan 10, 2024

Application Filed

Jul 22, 2025

Non-Final Rejection

Jan 22, 2026

Response after Non-Final Action

Jan 22, 2026

Response Filed

Apr 08, 2026

Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/436,225

Patent 12599615

USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES

2y 5m to grant Granted Apr 14, 2026

18/174,983

Patent 12604600

Organic Electroluminescent Element And Novel Iridium Complex

2y 5m to grant Granted Apr 14, 2026

17/054,468

Patent 12559494

NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE

2y 5m to grant Granted Feb 24, 2026

17/555,729

Patent 12552807

PCSK9 INHIBITORS AND METHODS OF USE THEREOF

2y 5m to grant Granted Feb 17, 2026

17/400,100

Patent 12545665

CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE

2y 5m to grant Granted Feb 10, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.

Prosecution Projections

3-4

Expected OA Rounds

74%

Grant Probability

99%

With Interview (+30.3%)

2y 4m

Median Time to Grant

Moderate

PTA Risk

Based on 1102 resolved cases by this examiner. Grant probability derived from career allow rate.